ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From
ScripAlmirall CEO Carlos Gallardo has added his voice to calls by leaders in the pharmaceutical industry for Europe to create a more innovation-friendly environment before it slips even further behind the
ScripJohnson & Johnson’s combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) in certain patients with non-small cell lung cancer (NSCLC) stands to expand its use as a first-line treat
Pink SheetCommercializing cell and gene therapies is notoriously challenging, and while pricing is often seen as a key problem, companies must also consider how their product fits in logistically with health ca